NO20052978L - Formulering som kan administreres gastrointestinalt, inneholdende gronn teekstrakt og en NO-donor. - Google Patents

Formulering som kan administreres gastrointestinalt, inneholdende gronn teekstrakt og en NO-donor.

Info

Publication number
NO20052978L
NO20052978L NO20052978A NO20052978A NO20052978L NO 20052978 L NO20052978 L NO 20052978L NO 20052978 A NO20052978 A NO 20052978A NO 20052978 A NO20052978 A NO 20052978A NO 20052978 L NO20052978 L NO 20052978L
Authority
NO
Norway
Prior art keywords
formulation
donor
green tea
tea extract
containing green
Prior art date
Application number
NO20052978A
Other languages
English (en)
Other versions
NO332734B1 (no
NO20052978D0 (no
Inventor
Heinz Schneider
Original Assignee
Fresenius Kabi De Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Kabi De Gmbh filed Critical Fresenius Kabi De Gmbh
Publication of NO20052978D0 publication Critical patent/NO20052978D0/no
Publication of NO20052978L publication Critical patent/NO20052978L/no
Publication of NO332734B1 publication Critical patent/NO332734B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives en formulering som kan administreres gastrointestinalt og omfatter grørm teekstrakt og minst en NO-donor som er et substrat for NO-syntetase, og/eller en forløper for derme. Formuleringen administieres før kirurgiske prosedyrer for å urmgå eUer redusere risikoen for postoperative komplikasjoner.
NO20052978A 2002-12-09 2005-06-17 Anvendelse av en blanding, som inneholder gronn teekstrakt og en NO-donor, for fremstilling av en formulering for a redusere risikoen for postoperative komplikasjoner eller for a unnga en slik risiko. NO332734B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10257360A DE10257360A1 (de) 2002-12-09 2002-12-09 Gastro-intestinal verabreichbare Formulierung und deren Verwendung
PCT/EP2003/012675 WO2004052352A1 (de) 2002-12-09 2003-11-13 Gastro-intestinal verabreichbare formulierung aus grüntee-extrakt und einen no-donor

Publications (3)

Publication Number Publication Date
NO20052978D0 NO20052978D0 (no) 2005-06-17
NO20052978L true NO20052978L (no) 2005-06-17
NO332734B1 NO332734B1 (no) 2012-12-27

Family

ID=32477462

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052978A NO332734B1 (no) 2002-12-09 2005-06-17 Anvendelse av en blanding, som inneholder gronn teekstrakt og en NO-donor, for fremstilling av en formulering for a redusere risikoen for postoperative komplikasjoner eller for a unnga en slik risiko.

Country Status (23)

Country Link
US (1) US20060121125A1 (no)
EP (1) EP1572175B1 (no)
JP (1) JP2006510640A (no)
KR (1) KR101031989B1 (no)
CN (1) CN100367941C (no)
AT (1) ATE345116T1 (no)
AU (1) AU2003288047B2 (no)
BR (1) BRPI0315075A8 (no)
CA (1) CA2499006C (no)
DE (2) DE10257360A1 (no)
DK (1) DK1572175T3 (no)
ES (1) ES2276136T3 (no)
HR (1) HRP20050511B1 (no)
IL (1) IL168854A (no)
IS (1) IS2432B (no)
MX (1) MXPA05006111A (no)
NO (1) NO332734B1 (no)
PL (1) PL212978B1 (no)
PT (1) PT1572175E (no)
RU (1) RU2314824C2 (no)
TW (1) TWI349563B (no)
WO (1) WO2004052352A1 (no)
ZA (1) ZA200501924B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1036746C2 (nl) * 2009-03-20 2010-09-21 Glnp Holding B.V. Kit van onderdelen bevattende l-glutamine en egcg.
WO2014150996A1 (en) * 2013-03-15 2014-09-25 Cba Pharma, Inc. Cancer treatment
WO2015094772A1 (en) * 2013-12-18 2015-06-25 Abbott Laboratories Methods for increasing skeletal muscle protein synthesis using green tea extract
US20210252423A1 (en) * 2018-06-21 2021-08-19 Gs Caltex Corporation Solvent composition for natural material extraction

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE502414C2 (sv) * 1990-05-28 1995-10-16 Ljungqvist Olle Medical Ab Användning av glukos för framställning av lösning för preoperativ administrering samt infusionslösning därför
GB9403935D0 (en) * 1994-03-01 1994-04-20 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
HUP9800049A3 (en) * 1995-02-23 1999-01-28 Novartis Nutrition Ag Amino acid compositions and use thereof in clinical nutrition, and use of the said amino acids for preparing pharmaceutical compns. for the diminution of tnf
US5656608B1 (en) * 1995-02-23 2000-09-26 Novartis Nutrition Ltd Amino acid compositions and methods of treatment using same
GB9510037D0 (en) * 1995-05-18 1995-07-12 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
JPH09227374A (ja) * 1996-02-28 1997-09-02 Taiyo Kagaku Co Ltd ストレスタンパク質産生抑制組成物
US6013273A (en) * 1997-01-27 2000-01-11 Novartis Nutrition Ag Treatment of endotoxic shock
JPH10248538A (ja) * 1997-03-10 1998-09-22 Cheil Sugar Co Ltd α−波増進飲料用組成物及びこれを含有する飲料
EP0875155A1 (en) * 1997-05-01 1998-11-04 N.V. Nutricia Peri-operative drink
US6147109A (en) * 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
US5904924A (en) * 1997-11-04 1999-05-18 Oncologics, Inc. Green nutritional powder composition
CA2368187A1 (en) * 1999-03-19 2000-09-28 Brigham And Women's Hospital, Inc. Upregulation of type iii endothelial cell nitric oxide synthase by hmg-coa reductase inhibitors
EP1136073A1 (en) * 2000-03-22 2001-09-26 N.V. Nutricia Compositions suitable for the treatment of damage caused by ischemia/reperfusion or oxidative stress
AU2001267836A1 (en) * 2000-07-05 2002-01-14 Kenji Ohnaka Preservation fluid for cells and tissues
DE60011261T2 (de) * 2000-07-14 2005-08-25 Nutri-Fit Gmbh & Co. Kg Grüntee-Extrakt zur Behandlung von Cyclosporin oder Ascomycin induzierten Nieren-Funktionsstörungen
US6423349B1 (en) * 2000-08-24 2002-07-23 Baxter International, Inc. Therapeutic nutrient composition for pre and post elective surgery

Also Published As

Publication number Publication date
NO332734B1 (no) 2012-12-27
RU2314824C2 (ru) 2008-01-20
BRPI0315075A8 (pt) 2017-12-19
NO20052978D0 (no) 2005-06-17
DE10257360A1 (de) 2004-07-08
HK1087913A1 (zh) 2006-10-27
CN100367941C (zh) 2008-02-13
ATE345116T1 (de) 2006-12-15
IL168854A (en) 2011-09-27
PL212978B1 (pl) 2012-12-31
HRP20050511B1 (en) 2008-01-31
EP1572175A1 (de) 2005-09-14
TW200418501A (en) 2004-10-01
TWI349563B (en) 2011-10-01
BR0315075A (pt) 2005-08-16
US20060121125A1 (en) 2006-06-08
JP2006510640A (ja) 2006-03-30
AU2003288047B2 (en) 2008-03-13
MXPA05006111A (es) 2005-08-16
WO2004052352A1 (de) 2004-06-24
KR101031989B1 (ko) 2011-05-02
RU2005111766A (ru) 2005-09-10
AU2003288047A1 (en) 2004-06-30
KR20050084207A (ko) 2005-08-26
EP1572175B1 (de) 2006-11-15
DE50305714D1 (de) 2006-12-28
HRP20050511A2 (en) 2005-10-31
ES2276136T3 (es) 2007-06-16
IS7836A (is) 2005-05-03
IS2432B (is) 2008-10-15
CN1703210A (zh) 2005-11-30
PL375734A1 (en) 2005-12-12
DK1572175T3 (da) 2007-03-19
CA2499006A1 (en) 2004-06-24
CA2499006C (en) 2011-04-19
ZA200501924B (en) 2005-11-30
PT1572175E (pt) 2007-01-31

Similar Documents

Publication Publication Date Title
WO2001062266A3 (en) Use of dpp-iv inhibitors for the treatment of diabetes
WO2003016335A3 (en) Irreversible cysteine protease inhibitors of legumain
EP1777203B8 (en) Ferroelectric capacitor, semiconductor device, and other element
TWI371782B (en) Nitride crystal, nitride crystal substrate, epilayer-containing nitride crystal substrate, semiconductor device and method of manufacturing the same
WO2005044199A3 (en) Combination of proton pump inhibitor and sleep aid
AU2003211575A1 (en) Semiconductor substrate, semiconductor chip, and semiconductor device manufacturing method
DK1435983T3 (da) Koncentrat omfattende grön te, drueskalsekstrakt og druekerneekstrakt, fremstilling og anvendelse heraf
WO2004071374A3 (en) Once a day orally administered pharmaceutical compositions
WO2007065156A3 (en) Pharmaceutical formulation for increased epithelial permeability of glucose-regulating peptide
WO2007092657A3 (en) Semiconductor device and method for incorporating a halogen in a dielectric
WO2005034861A3 (en) A dried biotherapeutic composition, uses, and device and methods for administration thereof
WO2005077365A3 (en) Novel uses for proton pump inhibitors
NO20052978L (no) Formulering som kan administreres gastrointestinalt, inneholdende gronn teekstrakt og en NO-donor.
AU2003292827A1 (en) Semiconductor device, dram integrated circuit device, and its manufacturing method
WO2002060906A3 (en) Crystal modification of olanzapine
WO2006042478A8 (fr) Inhibiteurs de petites molecules de la protease principale des coronavirus, leur preparation et utilisation
WO2004080414A3 (en) Composition and method for treating inflammations by reducing c-reactive protein
WO2008137015A3 (en) Anastomotic seal loading tool
WO2002076484A3 (en) Combination of a taxane and a cyclin-dependent kinase inhibitor
WO2006091847A3 (en) Clopidogrel base suitable for pharmaceutical formulation and preparation thereof
WO2005097153A3 (en) Extracts of passion fruit and uses thereof
WO2004034993A3 (en) Methods of preventing morbidity and mortality by perioperative administration of a blood clotting inhibitor
WO2006094736A3 (en) Alfuzosin controlled-release formulations
WO2003059650A3 (de) Hülle einer score-karte
NO20063006L (no) Faststoff doseringsform

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees